Details

Autor(en) / Beteiligte

• Bui, Thi Tho
• Fan, Yanjing
• Piao, Chun Hua
• Nguyen, Thi Van
• Shin, Dong-uk
• Jung, Sun Young
• Hyeon, Eunjin
• Song, Chang Ho
• Lee, So-Young
• Shin, Hee Soon
• Chai, Ok Hee

Titel

Piper Nigrum extract improves OVA-induced nasal epithelial barrier dysfunction via activating Nrf2/HO-1 signaling

Ist Teil von

• Cellular immunology, 2020-05, Vol.351, p.104035, Article 104035

Ort / Verlag

Netherlands: Elsevier Inc

Erscheinungsjahr

2020

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •The purpose of this study is to investigate the effect of Piper Nigrum on the nasal epithelial barrier function of the OVA-induced allergic rhinitis mouse model.•Piper Nigrum improves the epithelial barrier dysfunction via enhancing the activation of Nrf2/HO-1 signaling.•Piper Nigrum provides a promising strategy for epithelial barrier stabilization in airway diseases such as allergic rhinitis and asthma. Piper nigrum L. (Piperaceae) is commonly used as a spice and traditional medicine in many countries. It has been reported to have anti-oxidant, anti-bacterial, anti-tumor, anti-mutagenic, anti-diabetic, and anti-inflammatory properties. However, the protective role of P. nigrum on epithelial function of upper respiratory tract injury in an allergic rhinitis (AR) mouse model has been unclear. This study aims to investigate the effects of P. nigrum fruit extract (PNE) on the nasal epithelial barrier function of the upper respiratory tract in an ovalbumin (OVA)-induced AR model. AR mouse model was established by intraperitoneal injection with 200 µL saline containing 50 µg OVA adsorbed to 1 mg aluminum hydroxide, and intranasal challenge with 20 µL per nostril of 1 mg/ml OVA. Besides, mice were orally administrated once daily with PNE and dexamethasone (Dex) in 13 days. The nasal symptoms, inflammatory cells, OVA-specific immunoglobulins, cytokines, nasal histopathology, and immunohistochemistry were evaluated. The PNE oral administrations inhibited allergic responses via reduction of OVA-specific antibodies levels and mast cells histamine release, accordingly, the nasal symptoms in the early-phase reaction were also clearly ameliorated. In both nasal lavage fluid and nasal tissue, PNE suppressed the inflammatory cells accumulation, specifically with eosinophils. The intravenous Evans blue injection illustrated the epithelial permeability reduction of nasal mucosa layer in PNE-treated mice. Also; PNE treatments protected the epithelium integrity by preventing the epithelial shedding from nasal mucosa; as a result of enhancing the strong expression of the E-cadherin tight junction protein in cell-to-cell junctions, as well as inhibiting the degraded levels of zonula occludens-1 (ZO-1) and occludin into the nasal cavity. Additionally, PNE protected against nasal epithelial barrier dysfunction via enhancing the expression of Nrf2 activated form which led to increasing synthesis of the anti-inflammation enzyme HO-1. These obtained results suggest that PNE has a promising strategy for epithelial barrier stabilization in allergic rhinitis treatment.